歸創通橋-B(02190.HK)香港公開發售獲1190.37倍認購 上限定價每股42.7港元
格隆匯7月2日丨歸創通橋-B(02190.HK)發佈公吿，公司全球發售6000萬股股份，其中香港發售股份3000萬股，國際發售股份3000萬股，另有15%超額配股權；發售價釐定為每股發售股份42.70港元，每手買賣單位500股；摩根士丹利及中信證券為聯席保薦人，預期股份將於2021年7月5日於聯交所主板掛牌上市。
根據國際發售初步提呈發售的發售股份獲大幅超額認購，相當於國際發售項下初步可供認購發售股份總數的約22.5倍。香港公開發售項下初步提呈發售的香港發售股份獲大幅超額認購。合共接獲437,991份有效申請，認購合共71.42億股香港發售股份，相當於香港公開發售項下初步可供認購香港發售股份總數的約1190.37倍。
按發售價每股發售股份42.70港元，基石投資者已認購合共2635.6萬股發售股份，相當於全球發售完成後已發行發售股份的約43.93%；及全球發售完成後公司已發行股本總額的約8.15%，在各情況下均假設超額配售權未獲行使且不計及根據首次公開發售前購股權計劃將予發行的任何股份。
按發售價每股發售股份42.70港元計算，公司將收取的全球發售所得款項淨額估計約為23.975億港元(假設超額配售權未獲行使)。公司擬將該等所得款項淨額約37.0%分配予公司的核心產品(即蛟龍顱內取栓支架及Ultrafree DCB)；約11.0%將被分配予公司其他5款主要產品(即顱內動脈瘤栓塞彈簧圈、血流導向裝置、可回收腔靜脈濾器、外周靜脈支架系統及血管閉合裝置)的持續研發、生產及商業化，其中四款處於臨牀階段，一款處於註冊階段；約40.0%將被分配予公司其他38款產品及在研管線，以開發公司的產品組合，進而提供全線解決方案：約3.0%將分配予進一步升級研發設施，包括位於杭州及珠海的軟件及硬件基礎設施，以及在珠海計劃進行的辦公室擴建與升級；約4.0%將分配予潛在戰略收購、投資、授權引進或合作；及約5.0%將用於公司的營運資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
